WatersFRA:WAZ +6.44%92 EBITDA Margin % is 13.18% as of Mar. 2026, which is 62% below its 10-year median of 34.40. GuruFocus rates FRA:WAZ with a GF Score™ of 92/100 and a GF Value™ of €372.27 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Waters ranks better than 83.33% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Waters's EBITDA for the
three
months ended in Mar. 2026 was €144 Mil. Waters's Revenue for the
three
months ended in Mar. 2026 was €1,096 Mil. Therefore, Waters's EBITDA margin for the quarter that ended in Mar. 2026 was 13.18%.
Waters (FRA:WAZ) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Waters EBITDA Margin % Related Terms
Waters EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Waters's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:WAZ vs A, NTRA, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Waters's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waters EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Waters's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Waters's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Waters (FRA:WAZ) has a EBITDA Margin % of 13.18% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Waters and its competitors. This is 62% below median its historical median of 34.40. Over the past decade, Waters' EBITDA Margin % has ranged from 26.27 to 35.28. According to the industry distribution chart, Waters ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 16.7%.
Is Waters' EBITDA Margin % too high?
Waters' current EBITDA Margin % of 13.18% is 62% below median its 10-year median of 34.40. Over the past 10 years, this metric has ranged from a low of 26.27 to a high of 35.28. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Waters' value of 13.18% is 153.5% above this industry median. Based on the distribution chart, Waters ranks #34 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Waters has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Waters' EBITDA Margin % compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, Waters ranks #34 out of 204 companies for EBITDA Margin %. This places Waters in the top 17% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.20. Waters' value of 13.18% is 153.5% above this benchmark. Historically, Waters' own EBITDA Margin % has ranged from 26.27 to 35.28 over the past decade. While the company's 10-year median is 34.40 vs. the industry median of 5.20, Waters has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Waters's current EBITDA Margin % of 13.18% is 153.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Waters and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Waters's current EBITDA Margin % is 13.18%, which is 62% below median its own 10-year median of 34.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waters stock overvalued right now?
Based on GuruFocus' analysis, Waters (FRA:WAZ) is currently considered Modestly Undervalued. The stock's GF Value™ is €372.27, compared to a current price of €330.40 — trading 11.2% below its estimated fair value. The current EBITDA Margin % is 13.18%, which is 62% below median its 10-year median of 34.40 and 153.5% above the Medical Diagnostics & Research industry median of 5.20. Waters' overall GF Score™ is 92/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Waters (FRA:WAZ), the current EBITDA Margin % is 13.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Waters (FRA:WAZ) Overvalued in 2026?
Based on GuruFocus' analysis, Waters stock appears to be undervalued.
The current stock price of €330.40 is trading 11.2% below its estimated GF Value™ of €372.27.
GuruFocus considers Waters to be Modestly Undervalued.
Key valuation signals for FRA:WAZ:
EBITDA Margin %: 13.18% (62% below median its 10-year median of 34.40)
GF Value™: €372.27 vs. price of €330.40 (11.2% below fair value)
Industry Position: 153.5% above the Medical Diagnostics & Research median (#34 of 204)
No single metric tells the full story. See the FRA:WAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.
92GF Score
Get the complete analysis for FRA:WAZ
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:WAZ has been successfully added to your 
